The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC.

Aguiar, P N; Perry, L A; Penny-Dimri, J; Babiker, H; Tadokoro, H; de Mello, R A; Lopes, G L

Aguiar, P N; Perry, L A; Penny-Dimri, J; Babiker, H; Tadokoro, H; de Mello, R A; Lopes, G L.

Afiliação

Aguiar PN; Doctoral Grade Fellowship, Clinical Oncology Sector, Faculdade de Medicina do ABC, Santo André, Brazil.
Perry LA; Faculty of Medicine, Monash University, Mildura, Australia.
Penny-Dimri J; Faculty of Medicine, Monash University, Mildura, Australia.
Babiker H; Clinical Oncology Sector, Honor Health Scottsdale, Scottsdale, USA.
Tadokoro H; Clinical Oncology Sector, Universidade Federal de São Paulo, São Paulo, Brazil.
de Mello RA; Clinical Oncology Sector, Universidade do Algarve, Faro, Portugal.
Lopes GL; Clinical Oncology Sector at the University of Miami, Miami, USA.

Ann Oncol ; 29(4): 1078, 2018 04 01.

Article em En | MEDLINE | ID: mdl-29267838

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Ann Oncol Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google